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Results of a Multicentric In Silico Clinical Trial (ROCOCO)
Comparing Radiotherapy with Photons and Protons for Non-small
Cell Lung Cancer
Erik Roelofs, MSc,* Martijn Engelsman, PhD,† Coen Rasch, MD, PhD,‡ Lucas Persoon, MSc,*
Sima Qamhiyeh, PhD,* Dirk de Ruysscher, MD, PhD,* Frank Verhaegen, PhD,*§
Madelon Pijls-Johannesma, PhD,* and Philippe Lambin, MD, PhD*;
on behalf of the ROCOCO Consortium
Introduction: This multicentric in silico trial compares photon
and proton radiotherapy for non-small cell lung cancer patients.
The hypothesis is that proton radiotherapy decreases the dose and
the volume of irradiated normal tissues even when escalating to the
maximum tolerable dose of one or more of the organs at risk (OAR).
Methods: Twenty-five patients, stage IA-IIIB, were prospectively
included. On 4D F18-labeled fluorodeoxyglucose-positron emission
tomography-computed tomography scans, the gross tumor, clinical
and planning target volumes, and OAR were delineated. Three-
dimensional conformal radiotherapy (3DCRT) and intensity-modu-
lated radiotherapy (IMRT) photon and passive scattered conformal
proton therapy (PSPT) plans were created to give 70 Gy to the tumor
in 35 fractions. Dose (de-)escalation was performed by rescaling to
the maximum tolerable dose.
Results: Protons resulted in the lowest dose to the OAR, while
keeping the dose to the target at 70 Gy. The integral dose (ID) was
higher for 3DCRT (59%) and IMRT (43%) than for PSPT. The
mean lung dose reduced from 18.9 Gy for 3DCRT and 16.4 Gy for
IMRT to 13.5 Gy for PSPT. For 10 patients, escalation to 87 Gy was
possible for all 3 modalities. The mean lung dose and ID were 40
and 65% higher for photons than for protons, respectively.
Conclusions: The treatment planning results of the Radiation On-
cology Collaborative Comparison trial show a reduction of ID and the
dose to the OAR when treating with protons instead of photons, even
with dose escalation. This shows that PSPT is able to give a high tumor
dose, while keeping the OAR dose lower than with the photon modalities.
Key Words: In silico planning study, Multicentric trial, Lung
cancer, NSCLC, Radiotherapy, Particle therapy, Dose escalation.
(J Thorac Oncol. 2012;7: 165–176)
Despite the advances in lung cancer treatment, it remainsthe number one cause of death among cancer patients in
Europe and North America. Of these, 80% are categorized as
non-small cell lung cancers (NSCLCs).1,2 Different ap-
proaches in combining surgery, chemotherapy, and radiother-
apy to increase tumor control and to lower complication rates
are the subject of intense investigation.3
All over the world, proton and also carbon ion (C-ion)
radiotherapy is gaining interest and popularity. In the media,
it is sometimes bluntly stated that proton therapy yields the
best possible treatment for every cancer patient, the arguments
being solely based on the reduction of the dose administered to
the healthy tissue because of the physical characteristics of
charged particles. Current published comparative planning stud-
ies demonstrated the advantages in ballistic properties of particle
therapy (PT) over conventional photon radiotherapy. However,
these results were not sufficiently convincing, because they were
often monocentric studies performed with very limited patient
numbers and the treatment plans were mostly not performed
according to the current clinical guidelines.
Despite a long history of proton radiotherapy, recent
reviews have not shown a clear clinical evidence to imple-
ment charged PT on a large scale, mainly due to the lack of
randomized controlled trials (RCTs).4–7 However, it was con-
cluded from a comprehensive analysis of the current data that PT
was a promising treatment modality for NSCLC.8–10 Because
the cost of PT is considerably higher than conventional radio-
therapy with photons, questions arise about the (cost-) effective-
ness of this new technology and the need to perform RCTs.11,12
In response to the debate whether RCTs are needed for
charged particle treatment,13–19 a multicentric in silico clini-
cal trial named Radiation Oncology Collaborative Compari-
son (ROCOCO) was initiated in 2007. It emulates a real
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clinical trial comparing photon, proton, and C-ion therapy for
NSCLC, prostate, and head and neck cancer using the
collaborative multicentric in silico trials in radiotherapy
(MISTIR) framework (http://www.mistir.info). MISTIR uses
a secured central database with virtual patient material and
trial protocols comparable with the ones used in real RCTs. A
set of quality assurance procedures is available to prevent,
capture, and solve interoperability issues that may arise
during data exchange and analysis.20
With the use of MISTIR and participation of some of
the most experienced institutes in the field, we are able to
safely explore possible clinically acceptable treatment op-
tions that may pave the way for prospective RCTs with real
patients. To the best of our knowledge, no other study has
been performed where 14 (refer to the list of ROCOCO
consortium members) international radiotherapy centers
jointly perform such an in silico trial.
This report summarizes the current results of the dosi-
metric comparison of three-dimensional conformal photon
radiotherapy (3DCRT), intensity-modulated photon radio-
therapy (IMRT), and passive scattered proton therapy (PSPT)
of the NSCLC lung cohort of the ROCOCO trial. The
hypothesis is that PT decreases the dose to and the volume of
irradiated normal tissue while maintaining an iso-effective dose
to the tumor as well as when escalating dose to the maximum
tolerable dose (MTD). Consequently, the risk of side effects in
the surrounding normal tissue is expected to decrease.
PATIENTS AND METHODS
Study Design
An in silico clinical trial was performed, and data from
MAASTRO containing 4D F18-labeled fluorodeoxyglucose
(FDG)-positron emission tomography-computed tomography
(PET/CT) images were deidentified and centrally stored on
the secured MISTIR database as reported earlier.20 All vol-
umes were delineated at MAASTRO, and planning criteria
were described in a predefined protocol. The participating
institutes downloaded the datasets and performed treatment
planning according to the provided protocol using their own
clinical treatment planning system (TPS). By using the clin-
ically commissioned TPSs, the correctness of the dose cal-
culations was assured.
Next, the dose matrices in DICOM RT (radiotherapy
extension of the Digital Imaging and Communication in
Medicine standard) Dose format were uploaded back to the
database. Then, after being checked for consistency, the dose
matrices were used to calculate the dose-volume histograms
(DVHs) to derive the dose metrics for the final analysis. All
proton beam dose distributions were corrected to Gy(relative
biological effectiveness) by applying a relative biological
effectiveness factor of 1.1. The Gray unit (Gy) was used for
absorbed dose reporting of both modalities.
Patient Inclusion
Between October 2007 and June 2008, 25 stage I–III
NSCLC patients were included consecutively. No selection
was made regarding histology, stage, or location of the tumor,
resulting in a heterogeneous group of patients. An overview
of the patient characteristics is given in Table 1. All patients
were assumed to have a reasonable lung function (a forced
expiratory volume in 1 second 50% of predicted value and
a diffusing capacity of lungs for carbon monoxide [DLCO] not
corrected for alveolar volume 50%), so that a maximum
mean lung dose (MLD) of 19 Gy could be applied.21
For all patients, the 4D FDG-PET/CT was used to
determine the clinical staging of the tumors and individual
treatment margins.
Target and OAR Definitions
Target volumes, critical organs at risk (OAR), and other
normal tissues were delineated on each slice conform the
literature: tumor,22 lymph nodes,23 and OAR (spinal cord,
esophagus, lungs, and heart).24 The spinal cord was con-
sidered to be at the inner margin of the bony spinal canal
and was drawn throughout the whole CT scan. For the
esophagus, the contour of the outside muscle wall was
followed from the distal end of the larynx to the gastro-
esophageal junction. Contouring of the lungs was done
using automatic delineation by thresholding on the TPS
with a manual correction where needed. The heart was
contoured from the apex to the origin of the large vessels,
including the pericardium.
Individual peak-to-peak tumor motion was determined
using the 4D CT, and delineations of the tumor and OAR
were projected on the midventilation phase (50% exhale).22
For all patients, a gross tumor volume (GTV) was defined
based on the 4D FDG-PET/CT data. The GTV was defined as
the primary tumor on CT and lymph nodes positive on a PET
scan or proven to be positive on mediastinoscopy, transoe-
sophageal, or transbronchial puncture. No elective nodal
irradiation was performed. Syngo TrueD (Siemens Medical
Solutions, Malvern, PA) was used to automatically define the
PET positive areas by using a pathology-validated source-to-
background method.25–27
The clinical target volume (CTV) was defined as the
GTV with a margin of 5 mm. Next, the individual, anisotro-
pic planning target volume (PTV) margins for photons were
calculated in three directions (cranial-caudal, left-right, and
anterior-posterior) using a margin recipe (refer to the Appen-
dix, Eq. A1). For protons, the margins from CTV to PTV are
determined differently, to incorporate a lateral smearing fac-
tor and range uncertainties (refer to the treatment planning
section hereafter and the Appendix).
Treatment Planning
Treatment planning was performed for 3DCRT, IMRT,
and PSPT at MAASTRO, the Netherlands Cancer Institute,
and the Massachusetts General Hospital (MGH), using XiO
(v4.34, CMS Software, St. Louis, MO), Pinnacle (ADAC
Laboratories, Milpitas, CA), and a modified proton enabled
version of XiO (v4.2.1), respectively. For the photon dose
calculations, a multigrid superposition algorithm28 or equiv-
alent was used to account for tissue heterogeneity. Proton
dose calculations were performed using a modified version of
the XiO pencil beam algorithm with one-dimensional density
corrections. The dose matrices, with a 3  3  3-mm3 grid
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size, were uploaded in DICOM RT Dose format onto the
secured central server.
For all modalities, the prescribed dose (PD) was 70 Gy
to the PTV in 2 Gy fractions, once a day. Criteria for
minimum and maximum dose were defined according to a
modified ICRU 50 protocol29: D98 95% and D2 107% of
the PD. The maximum dose (D2) to the spinal cord and
esophagus equaled 54 and 80 Gy, respectively, using 2 Gy
fractions, independent of the volume. For the lungs, the MLD
was limiting to a biologically equivalent dose in 2 Gy
fractions (EQD2) of 19 Gy. The MLD volume was defined as
the volume of both lungs minus the GTVs. For the heart,
three DVH metrics were defined: V60 33%, V45 66%, and
V40 100%.
Two plans were created per patient. First, a fixed PD of
70 Gy to the tumor was used. Next, plans were upscaled or
downscaled by adapting the fraction dose to fulfill all criteria
of the OARs. The mean CTV dose was then reported as
MTD. A maximum fraction dose of 4 Gy was considered,
resulting in an EQD2 to the tumor of 163 Gy. Table 2
summarizes the physical and corresponding EQD2-planning
criteria for the target and OAR.
Photons
3DCRT plans were created at MAASTRO as per the
clinical guidelines. The plans consisted of multiple, opti-
mized coplanar beams using a multileaf collimator and
wedges to shape the dose conformally to the target. In many
TABLE 1. Patient Characteristics of the Datasets Showing Histology, TNM Classification, Staging, Top–Top Amplitudes of the
Tumor Measured on the 4D PET/CT Scan, and the Derived Anisotropic Margins for Photons





CC LR AP CC LR AP
1 Squamous T3N2M0 IIIA 20 5 10 10 6 8
2 Adeno T2N3M0 IIIB 4 3 9 8 6 8
3 Adeno T2N2M0 IIA 8 3 5 8 6 7
4 Squamous T4N0M0 IIIB 3 2 2 7 6 7
5 Squamous T2N1M0 IIB 8 4 6 8 6 7
6 Large cell T4N2M0 IIIB 5 2 3 8 6 7
7 Squamous T4N0M0 IIIB 14 3 4 9 6 7
8 Large cell T1N2M0 IIIA 17 10 20 10 7 10
9 Large cell T4N3M0 IIIB 17 3 5 10 6 7
10 Large cell T2N2M0 IIIA 8 2 2 8 6 7
11 Large cell T2N3M0 IIIB 13 2 1.5 9 6 7
12 Large cell T1N3M0 IIIB 4.5 3 3 8 6 7
13 Large cell T1N2M0 IIIA 7 2 2 8 6 7
14 Adeno T2N2M0 IB 3 2 2 7 6 7
15 Squamous T2N0M0 IIIA 11 3 4 9 6 7
16 Adeno T4N2M0 IIIB 6 3.5 3 8 6 7
17 Large cell T2N3M0 IIIB 6 2 2 8 6 7
18 Squamous T1N0M0 IA 4 5 6 8 6 7
19 Squamous T2M0N0 IB 1 1 1 7 6 7
20 Large cell T2N0M0 IB 5 2 2 8 6 7
21 Large cell T1N2M0 IIIA 10 7 3 8 6 7
22 NSCLC NOS T4N3M0 IIIB 4.5 2.5 4 8 6 7
23 Adeno T1N1M0 IIA 5 4 2 8 6 7
24 NSCLC NOS T4N3M0 IIIB 4.5 6 4 8 6 7
25 Large cell T2N2M0 IIIA 3 1 1.5 7 6 7
CC, cranial-caudal; LR, left-right; AP, anterior-posterior; Squamous, squamous cell carcinoma; Adeno, adenocarcinoma; Large cell, large cell carcinoma; NSCLC NOS,
non-small cell lung cancer not otherwise specified; CTV, clinical target volume; TNM, tumor, node, metastasis; PET, positron emission tomography; CT, computed tomography.
TABLE 2. Conversion Table Between EQD2 and Physical
Dose for Target and OAR
Structure
of Interest / (Gy) Criterion EQD2 (Gy)
Physical Dose at
35 Fractions (Gy)
PTV 10 D2 163 140
Lungs 3 MLD 19 Depends on distributiona
D33% 60 63
Heart 3 D67% 45 51
D100% 40 46
Esophagus 3 D2 80 77
Spinal cord 2 D2 54 59
a The EQD2 of the MLD was calculated using the full 3D physical dose distribution
and recalculating the equivalent dose at each point.
EQD2, equivalent dose in 2 Gy fractions; OAR, organs at risk; MLD, mean lung
dose; PTV, planning target volume.
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cases, additional small beams from the same directions were
used with limited dose to “pull” the isodoses around the PTV.
The energy of the photon beams was almost always 10 MV.
IMRT plans were created at the Netherlands Cancer
Institute consisting of six to ten 10-MV beams. The beam
configuration was mainly coplanar with a few exceptions.
The collimator was rotated to fit best the shape of the target
and OARs. For the optimization, the criteria as given above
were used in combination with constraints to some additional
structures to control the dose to certain areas or force rapid
dose fall-off around the PTV. Initial optimization was done
using 30 segments with 25-cm2 size. When needed, the
number of segments was increased to 50, while the segment
size could be decreased to 12 cm2.
Protons
The passive-scattered proton plans were planned at
MGH using the XiO TPS. Each plan consisted of at least two
(preferably three) beam directions to spread out the dose to
normal tissues. Using a midventilation CT scan of the tumor,
first, for each beam, an aperture, range compensator, range
and modulation were chosen to conform the 95% isodose
level as closely as possible to the target, that is, the CTV.
Second, margins were applied to the aperture, the range
compensator, and both the range and modulation width taking
setup errors and breathing motion into account.
Beam directions that are parallel to density interfaces
such as the lung and mediastinum were avoided because of
the large range uncertainties even for small setup errors.
Because of the low density of inflated lung (e.g., 0.25
g/cm3), overshoot due to range uncertainties and applied
smearing results in a substantial volume of lung receiving full
dose for a given beam direction. Therefore, the beam angles
were intentionally aimed toward the mediastinum. Refer to the
Appendix for a detailed description of the proton planning
process.
Analysis
To minimize the uncertainty in the analysis, all the
DVH metrics (refer to Table 3 and 4) were centrally derived
by MAASTRO from the 3D-dose matrices. Because the PTV
is different for photon and proton modalities due to different
margin algorithms, we chose the CTV for target comparison.
We compared integral doses (ID), defined as the mean dose to
the imaged patient, as dosimetric estimate for normal tissue
toxicity differences between the three modalities.
For an estimation of the differences in the therapeutic
windows of the treatment modalities, we introduced surrogate
therapeutic indices (TIs) for the lungs, esophagus, and spinal
cord. These were derived by dividing the mean dose to the
target by the essential dose metric of the structure. For
example, for the lungs, this would result in a TIMLD defined
by the MTD over the MLD.
To quantitatively assess the differences in conformity
of the different treatment modalities, various indices have
been proposed in the literature.30 Because we wanted to
compare the different treatment modalities based on target
coverage and unwanted dose to the noncritical as well as the
critical normal tissue (OARs), we used a “conformation








where CTV95 and V95 are the volume of the CTV and the
overall volume, respectively, receiving minimally 95% of the
target dose. Refer to the Appendix or Ref. 31 for a more
elaborate description.
To investigate the volume of the low-dose region in the
patient, a sparing index (SPIN50/10) was used32:
SPIN50/10  1  V10
50 (2)
where V10
50 is the ratio of the volume of tissue that receives
between 10 and 50% of the PD to the irradiated volume. The
irradiated volume was defined as the volume of tissue that
receives at least 0.5% of the PD.
For both CN and SPIN50/10, a value of 1 would indicate
a perfect, theoretical dose distribution solely around the target
and none in the healthy tissue.
Two-tailed, signed-rank Wilcoxon tests were calculated
using SPSS (version 15, Chicago, IL) and Matlab (The
MathWorks, Natick, MA) to determine the significance of
pairwise differences between modalities. The values of p less
than 5/3% were considered significant.
We must note that, in general, some of the mentioned
metrics are not suitable as absolute measures of plan quality
or treatment modality performance. For instance, when con-
sidering volumes of OAR, they can depend on the imaged
patient volume (e.g., spinal cord) and of course the anatom-
ical differences of the patients. In this study, we used these
metrics in a relative way and compared these metrics pairwise
as indicated above. This way, a statement of better plan
quality is possible.
RESULTS
Of the 25 included patients for the iso-effective proto-
col (Table 1), all were planned with 3DCRT and IMRT and
23 with PSPT. Two patients with tumors located very crani-
ally were excluded from proton planning. In real life, these
patients would not be treated with PSPT because of the
limited beam directions possible and because of remaining
range uncertainties due to accuracy in the positioning of the
arms. Because of the pairwise analysis, we report on the
remaining 23 corresponding datasets.
In Figure 1, mid-PTV dose distributions are shown for
three typical cases. In general, IMRT showed a more confor-
mal dose compared with 3DCRT and both showed a fairly
large low-dose region outside the target. PSPT showed its
typical clear-edged beams with no exit dose. Figure 2 shows
the DVHs for one of the patients (#2).
When irradiating with protons, it was found (Table 3)
that, while prescribing the same dose to the target, the
average ID was significantly lower than for 3DCRT (59%,
p  0.001) and IMRT (43%, p  0.001). Except for V30Gy,
all lung volume metrics were significantly higher for photons
than for protons. The average MLD was significantly higher
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for 3DCRT (40%; p  0.001) and IMRT (21%; p  0.001)
when compared with PSPT. This resulted in a significantly
higher TI-MLD for PSPT when compared with 3DCRT (51%,
p  0.001) or IMRT (39%, p  0.001).
For the spinal cord and esophagus, the average maxi-
mum doses (D2) did not differ significantly between the three
modalities. The average mean dose to the esophagus was
slightly larger for 3DCRT (16%, p  0.001) and IMRT
(6.6%, p  0.02) than for PSPT. All average heart metrics
were significantly lower for protons when compared with
photons, except for the V65Gy, which was 23% lower for
IMRT (p  0.002). The average TIDmean for both photon
modalities was 44 times lower (p  0.001) than for protons.
With respect to the conformity of the three different
modalities, it was shown that IMRT had an average 50%
higher CN (p  0.001), while 3DCRT scored equally com-
pared with PSPT. Also, the SPIN50–10 was significantly
worse for PSPT than for 3DCPT and IMRT: 0.61  0.09
versus 0.70  0.05 (p  0.002) and 0.72  0.04 (p  0.001),
respectively.
After upscaling or downscaling all plans to clinically
acceptable MTD by fulfilling all planning criteria, the PD to
TABLE 3. DVH Metrics of the Photon and Proton Treatment Plans for the Prescribed and Maximum Tolerable Dose






PSPT3DCRT IMRT 3DCRT IMRT
Target (CTV)
Dmean 71.3 (1.0)
a 70.7 (0.9) 70.3 (0.7) 75.0 (22.2) 81.5 (20.8) 75.0 (21.2)
D2 73.9 (1.4)
a 73.1 (1.9)a 72.0 (0.8) 77.6 (22.2) 84.2 (21.6) 76.7 (21.4)
D98 68.9 (1.1) 68.7 (1.1) 68.7 (1.0) 72.6 (22.2) 79.2 (20.5) 73.3 (21.0)
CN 0.25 (0.07) 0.38 (0.10)a 0.25 (0.08) 0.25 (0.07) 0.38 (0.10)a 0.25 (0.08)
Patient
ID 11.0 (5.4)a 9.9 (4.4)a 6.9 (3.9) 10.2 (3.2)a 10.6 (3.7)a 6.8 (3.1)
SPIN50–10 0.70 (0.05)
a 0.72 (0.04)a 0.61 (0.09) 0.71 (0.05)a 0.73 (0.04)a 0.62 (0.09)
TIID 8.6 (5.2)




a 16.3 (7.7) 16.8 (8.9) 20.3 (7.6)a 17.7 (6.6) 16.7 (8.1)
V20Gy 27.1 (12.6)
a 23.4 (10.2)a 20.5 (10.4) 26.4 (9.5)a 25.0 (9.3)a 20.2 (10.2)
V13Gy 37.0 (17.5)
a 32.1 (11.8)a 23.3 (12.0) 36.1 (12.8)a 34.1 (10.2)a 23.1 (11.5)
V5Gy 53.1 (17.0)
a 56.9 (12.9)a 27.5 (13.9) 53.2 (15.5)a 59.1 (10.2)a 27.5 (13.7)
MLD 18.9 (7.3)a 16.4 (5.5)a 13.5 (6.2) 18.2 (4.1)a 17.9 (4.1)a 13.6 (5.6)
TIMLD 4.5 (1.9)
a 4.9 (2.0)a 6.8 (3.9) 4.5 (1.9)a 4.9 (2.0)a 6.8 (3.9)
Spinal cord
D2 40.0 (21.4) 42.6 (9.6) 37.9 (23.2) 37.0 (17.1) 46.8 (6.3)
a 35.5 (18.1)
TID2 6.7 (15.2) 1.8 (0.7)
a 31.7 (105) 6.8 (15.7) 1.8 (0.7)a 52.1 (198)
Esophagus
D2 65.0 (15.7) 64.7 (15.8) 63.6 (17.9) 64.5 (13.8) 70.3 (11.0) 65.7 (17.3)
Dmean 28.3 (13.9)
a 26.0 (12.1) 24.4 (13.7) 26.3 (9.4)a 27.5 (11.1)a 23.7 (11.7)
V55Gy 31.0 (20.2) 26.4 (18.1) 28.3 (19.1) 22.0 (16.2) 27.3 (17.3) 22.2 (16.7)
V35Gy 38.3 (22.7)
a 34.9 (19.9) 35.3 (20.3) 37.8 (20.2) 37.0 (17.4) 35.3 (18.7)
TID2 1.3 (0.8) 1.3 (0.7) 2.0 (4.1) 1.3 (0.8) 1.3 (0.7) 2.0 (4.1)
Heart
Dmean 15.3 (11.6)
a 14.3 (10.3)a 7.6 (7.2) 14.3 (9.5)a 15.3 (10.0)a 7.5 (7.1)
V65Gy 4.4 (5.5)
a 2.3 (3.3)a 3.0 (4.0) 2.1 (3.0) 2.0 (2.9) 2.3 (4.2)
V45Gy 13.3 (13.3)
a 9.1 (9.3)a 6.2 (6.5) 10.1 (9.6)a 9.6 (8.5)a 6.1 (6.3)
V40Gy 15.1 (14.5)
a 11.5 (11.7)a 7.2 (7.2) 12.4 (10.8)a 12.4 (10.9)a 7.2 (7.1)
V30Gy 19.5 (17.2)
a 17.0 (16.1)a 12.0 (13.4) 18.5 (15.1)a 18.5 (15.4)a 11.7 (13.1)
V20Gy 27.0 (23.7)
a 25.3 (22.2)a 15.1 (15.6) 26.5 (19.8)a 27.6 (21.3)a 15.0 (15.4)
V10Gy 40.9 (31.8)
a 41.0 (31.9)a 18.1 (17.5) 40.7 (30.6)a 45.0 (33.4)a 18.1 (17.3)
TIDmean 13.1 (16.8)
a 13.0 (14.9)a 572 (2074) 13.1 (16.8)a 13.0 (14.9)a 572 (2074)
Data for the target and the organs at risk are given as mean physical dose values with the standard deviation in parenthesis. aSignificant differences (p  0.0167) of the photon
vs. the proton results.
PD, prescribed dose; MTD, maximum tolerable dose; 3DCRT/IMRT/PSPT, 3D conformal photon/intensity-modulated photon/3D passive scattered proton radiotherapy; Dx, dose
(Gy) given to x% (or mean) of the volume; CN, conformation number (Eq. 4); ID, integral dose in Gy; TIy, therapeutic index (MTD/y); VzGy, percent volume of the total organ’s
volume that receives more than z Gy (for the lung results, the volume was taken as both lungs minus the PTV for photons); MLD, mean lung dose in Gy (lung volume taken as both
lungs minus the GTVs); CTV, clinical target volume.
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the tumor of 70 Gy could be increased for 52, 83, and 61% of
the patients for 3DCRT, IMRT, and PSPT, respectively
(Table 3). The other patients received the PD or lower. Refer
to Figure 2 for DVHs of such a case (#2).
The mean MTD was 8.6% higher for IMRT when
compared with PSPT, although this was not significant. The
3DCRT MTD did not differ from PSPT. The ID was higher
again for both photons modalities when compared with pro-
tons (p  0.005). Once more, all lung volume metrics were
significantly higher for photons than for protons, except for
V30Gy. The average MLD was significantly higher for
3DCRT (34%; p  0.001) and IMRT (32%; p  0.001) when
compared with PSPT.
For the spinal cord, the average maximum dose (D2)
was 42% higher for IMRT than for PSPT (p  0.005). The
average mean dose to the esophagus was larger for 3DCRT
(11%, p  0.007) and IMRT (16%, p  0.005) than for
PSPT. All average heart metrics were significantly lower for
TABLE 4. DVH Metrics of the Photon and Proton Treatment Plans, Split for Plans Where all Modalities Simultaneously Could
Escalate the Dose to the Tumor and Some That Did Not
One or More Modalities Had
to De-escalate (n  13)
All Modalities Could






PSPT3DCRT IMRT 3DCRT IMRT
Target (CTV)
Dmean 66.7 (22.8) 76.6 (19.2) 64.6 (10.1) 85.8 (17.0) 87.9 (22.0) 88.5 (24.5)
D2 69.4 (22.7) 79.0 (19.6) 66.2 (10.5) 88.3 (17.3) 91.1 (23.2) 90.4 (24.6)
D98 64.3 (22.8) 74.4 (19.0) 63.1 (10.0) 83.5 (16.7) 85.6 (21.7) 86.4 (24.5)
CN 0.26 (0.08) 0.41 (0.12)a 0.28 (0.10) 0.23 (0.06) 0.34 (0.07)a 0.23 (0.05)
Patient
ID 11.8 (3.1)a 12.3 (3.7)a 8.1 (3.1) 8.2 (2.1)a 8.3 (2.1)a 5.0 (2.0)
SPIN50–10 0.69 (0.05)
a 0.72 (0.04)a 0.63 (0.08) 0.74 (0.04)a 0.74 (0.03)a 0.60 (0.10)
TIID 6.7 (5.4)
a 7.4 (5.4)a 11.5 (11.6) 11.1 (3.9)a 11.4 (4.6)a 20.2 (9.9)
Organs at risk
Lung
V30Gy 22.6 (8.4) 18.8 (6.8) 18.8 (9.2) 17.2 (5.4) 16.4 (6.4)
a 13.9 (5.9)
V20Gy 30.1 (9.9)
a 26.9 (9.7) 23.4 (11.2) 21.6 (6.7)a 22.5 (8.5)a 16.1 (7.2)
V13Gy 40.2 (14.5)
a 36.5 (10.3)a 27.1 (12.5) 30.8 (7.9)a 31.0 (9.6)a 17.8 (7.8)
V5Gy 60.4 (15.7)
a 63.7 (7.6)a 32.3 (15.1) 43.9 (9.4)a 53.2 (10.5)a 21.4 (9.0)
MLD 19.8 (3.6)a 19.5 (3.3)a 15.4 (5.7) 16.1 (3.8)a 15.8 (4.2)a 11.3 (4.8)
TIMLD 3.6 (1.8)
a 4.2 (1.9)a 4.9 (2.5) 5.6 (1.5)a 5.9 (1.9)a 9.2 (4.2)
Spinal cord
D2 42.3 (16.2) 48.3 (4.8) 44.7 (13.2) 30.1 (16.5) 44.8 (7.7)
a 23.6 (17.1)
TID2 6.9 (19.5) 1.6 (0.37) 1.7 (0.87) 6.7 (9.5) 2.1 (0.9)
a 117 (295)
Esophagus
D2 59.0 (9.5) 69.8 (11.5) 61.2 (19.8) 71.7 (15.6) 71.0 (10.7) 71.5 (11.9)
Dmean 31.2 (7.6) 33.1 (10.7) 29.8 (10.7) 20.0 (7.9)
a 20.2 (6.6)a 15.9 (7.7)
V55Gy 25.5 (18.5) 35.1 (17.1) 26.8 (19.0) 17.6 (12.0) 17.2 (11.8) 16.3 (11.6)
V35Gy 49.5 (16.3) 45.5 (17.7) 45.5 (17.2) 22.5 (13.5) 26.0 (9.1)
a 22.0 (10.6)
TID2 1.2 (0.78) 1.2 (0.81) 2.5 (5.4) 1.3 (0.8) 1.3 (0.59) 1.3 (0.72)
Heart
Dmean 17.3 (9.3)
a 18.9 (9.8)a 9.6 (7.9) 10.4 (8.7)a 10.5 (8.5)a 4.7 (5.0)
V65Gy 1.3 (2.5) 2.2 (3.6) 2.5 (5.4) 3.1 (3.5) 1.7 (1.7) 2.0 (2.1)
V45Gy 10.9 (9.1) 12.5 (9.0)
a 7.8 (7.3) 9.0 (10.6)a 5.7 (6.1) 4.0 (4.0)
V40Gy 14.3 (10.1) 16.3 (11.5)
a 9.2 (8.2) 10.0 (11.6)a 7.2 (7.9)a 4.6 (4.6)
V30Gy 23.3 (14.9) 24.1 (15.6)
a 15.5 (15.3) 12.2 (13.4)a 11.3 (12.2)a 6.7 (7.7)
V20Gy 33.2 (19.2) 35.0 (21.0)
a 19.8 (17.2) 17.8 (17.8)a 17.9 (18.3)a 8.8 (10.5)
V10Gy 53.2 (31.8)
a 56.1 (31.6)a 23.6 (19.0) 24.4 (20.7)a 30.5 (31.4)a 10.9 (12.1)
TIDmean 11.3 (19.8)
a 9.0 (12.6)a 941 (2744) 15.4 (12.3)a 18.0 (16.8)a 91.5 (126.8)
Data for the target and the organs at risk are given as mean physical dose values with the standard deviation in parenthesis. aSignificant differences (p  0.0167) of the photon
vs. the proton results.
PD, prescribed dose; MTD, maximum tolerable dose; 3DCRT/IMRT/PSPT, 3D conformal photon/intensity-modulated photon/3D passive scattered proton radiotherapy; Dx, dose
(Gy) given to x% (or mean) of the volume; CN, conformation number (Eq. 4); ID, integral dose in Gy; TIy, therapeutic index (MTD/y); VzGy, percent volume of the total organ’s
volume that receives more than z Gy (for the lung results, the volume was taken as both lungs minus the PTV for photons); MLD, mean lung dose in Gy (lung volume taken as both
lungs minus the GTVs); CTV, clinical target volume.
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protons when compared with photons, except for the V65Gy,
which did not differ significantly.
Because of the rescaling of the dose matrices, the DVH
metrics that are based on relative dose levels or ratios typi-
cally do not change. One exception is the TID2 for the spinal
cord where the accuracy of the D2 is limited by some very
small irradiated volumes.
For 10 patients (two stage I, one stage II, and seven
stage III), all modalities could escalate the dose to an MTD of
approximately 87 Gy (Table 4). The average ID was about
65% higher for photons than for protons (p  0.005). The
MLD was 42% higher for 3DCRT (p  0.007) than for PSPT,
whereas it was 40% higher for IMRT (p  0.005). The TIID
and TIMLD were nearly double of those of the nonescalated
group. For the spinal cord, the maximum dose was 90%
higher for IMRT than for PSPT (p  0.005). For the esoph-
agus, the maximum dose was approximately 71.5 Gy for all
modalities. The mean dose to the heart for photons was
double the dose for protons, whereas the V40Gy was 117%
higher for 3DCRT (p  0.013) and 57% higher for IMRT
(p  0.013) than for PSPT.
FIGURE 1. Comparison of dose dis-
tributions of three-dimensional con-
formal photon radiotherapy (3DCRT),
intensity-modulated radiotherapy
(IMRT), and passive scattered confor-
mal proton therapy (PSPT) treatment
plans (columns) for three cases
(rows). The target is shown (red) with
isodose lines of 1, 10, 25, 50, and
67 Gy.
FIGURE 2. Dose-volume histo-
grams (DVHs) for patient #2 where
the prescribed dose of 70 Gy re-
sulted in exceeding the critical
mean lung dose (MLD) level (up-
per). Lowering the dose to the max-
imum tolerable dose resulted in
lower DVH (bottom), showing
larger under-dosage for three-di-
mensional conformal photon radio-
therapy (solid) than for intensity-
modulated radiotherapy (dashed) or
passive scattered conformal proton
therapy (dotted). *MLD refers to
the DVH of both left and right lung
volumes minus the gross tumor
volume.
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Further subgroup analysis based on tumor volume,
location, or stage did not provide new information and is
omitted from this report.
DISCUSSION
With the first results from 23 cases of the lung cohort of
the ROCOCO trial, we have shown that for the treatment of
NSCLC, stage I to III, proton radiotherapy is superior to
photon radiotherapy, in terms of reduction of the normal
tissue dose. Based on the ID, an absolute improvement of 3
to 4 Gy was seen for protons, resulting in an improved
therapeutic index in the order of 15 compared with 9.
In the current literature, with a few exceptions,33–35 10
or less patients were used in the published treatment planning
comparisons. Furthermore, in most of the published articles,
it is unclear what the selection criteria were of the included
patients, possibly introducing selection bias. Publications
dating before 2000 did not consider intensity-modulated ra-
diation therapy as a modality for photon therapy or intensity-
modulated PT. By using a multicentric approach, with con-
sensus on a predefined protocol and a relatively large amount
of patients, a high level of confidence was achieved in this
study as the established clinical experience of the participants
was used.
In this study, we found that the average V20Gy of the
lungs were lower for both IMRT and PSPT compared with
3DCRT (16.3, 16.8, and 21%, respectively). Regarding the
MLD, it was found that this was lowest for PSPT (13.5 Gy)
when compared with 3DCRT (18.9 Gy) or IMRT (16.4 Gy).
Previous research has shown that the V5 of the lungs was also
associated with lung toxicity.36 This study showed that the V5
for protons was less than half the value for both photon
modalities.
Although the average maximum dose to the spinal cord
did not significantly change between all three modalities, it
was shown that the average of the corresponding individual
therapeutic index was significantly higher for PSPT (31.7)
than for IMRT (1.8). This indicates that there are a few
outliers present in the derived metrics.
Furthermore, the maximum dose to the esophagus was
nearly equal for all three modalities. The V55Gy appeared to
be lowest for IMRT (26.4%). When considering the V35Gy,
however, it was equal for IMRT and PSPT (35%). The mean
heart dose for photons was nearly double the dose of protons,
whereas the V40Gy, which is known for its correlation to heart
toxicity, was 110 and 60% higher for 3DCRT and IMRT,
respectively, than for PSPT.24
It is expected that the lower dose to the normal
tissues with proton therapy will lower the probability of
normal tissue complications and result in a better quality
of life in an iso-effective setting. Clinical validated models
have been published showing this for a variety of acute and
late toxicities.37– 40
Radiation therapy is known for its statistically signifi-
cant increased risk of secondary malignancies.41 The hypoth-
esis of reduced late side effects with proton therapy has been
investigated intensely and tends to be correctly supported,
although large uncertainties in the relative biological effect,
among others, remain.42–46 In addition, improvements in the
treatment delivery equipment further reduce the amount of
secondary neutron production, which is the main contributor
to the scattered dose to the normal tissue.47–49 Although the
occurrence of secondary tumors for lung cancer patients
could be considered irrelevant due to the short life expec-
tancy, the expected reduced carcinogenic risk should be
mentioned with respect to the changing NSCLC population
and overall treatment improvements.
Another advantage of the small low-dose volume and
limited number of beams for protons is that it offers the
opportunity to better reirradiate for loco-regional metastasis.
The increased therapeutic ratios showed that there is a room
for iso-toxic dose escalation with protons for certain patients.
A unicentric study including a selection of 15 stage III
patients has shown that dose escalation from 63 to 74 Gy was
possible with PSPT while keeping normal tissue toxicity
lower than with 3DCRT or IMRT.33 Early results of a
subsequent phase II trial show that a dose prescription to 74
Gy is well tolerated with proton therapy.50
The current report predicts that this still holds for
MTDs exceeding these levels with about 10 Gy. For 40% of
the patients, dose escalation was possible to a mean level of
more than 85 Gy for all modalities. With dose levels of such
ablative magnitude, while still maintaining the dose to the
OAR below a toxic level, it is expected that local tumor
control will significantly be increased and consequently will
lead to a further improved survival with acceptable toxicity.
A phase II dose escalation trial is currently being performed
to investigate sub-boosting of high FDG-PET uptake regions
to such high doses with IMRT.51 PSPT will not be a part of
this trial because range uncertainties make it nearly impossi-
ble to ensure a certain limited dose to an OAR by means of
forward planning.
When the treatment plans of the three modalities were
evaluated for possible dose escalation, it showed that some-
times the dose could be increased for one modality while it
had to be lowered for another. The fact that this heterogeneity
cannot be predicted beforehand makes generalization of the
achieved results difficult. This raises the demand for an
individualized approach when trying to classify eligibility of
a patient to receive proton therapy instead of less expensive
photon therapy (see Slides, Supplemental Digital Content 1,
http://links.lww.com/JTO/A179, which show a Proton ther-
apy reimbursement decision tree for the Netherlands and
Figures 1 and 2).
The performance of the CN and SPIN50–10 is worse
when using PSPT instead of 3DCRT or IMRT. The error
margins that are needed to compensate in depth and width
and the fact that only two to three beams are used to generate
an irradiated volume that exceeds the PTV used for photons.
However, even though PSPT suffers from these disadvan-
tages, the dose to the normal tissues remains much lower than
for 3DCRT and IMRT. This indicates that the use of confor-
mity and dose spill indices is useful for plan comparison but
they do not cover the full plan evaluation and cannot by
themselves indicate prevalence of either treatment modality.
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One might argue that PSPT is not the latest and most
advanced type of PT, but despite this, the current results show
that it is favorable in terms of normal tissue dose reduction
when compared with photon radiation therapy. It could be
argued that if results were derived from modern scanning
proton beam therapy, the dose distributions could improve
due to reduced secondary neutron production47,52 and im-
proved conformity. Recent publications show indeed that
intensity-modulated proton therapy (IMPT) is able to lower
the dose to the normal tissue and allows dose escalation up to
88 Gy for a selection (n  20) of extensive stage IIIB NSCLC
patients.53
For stage I NSCLC patients, stereotactic radiotherapy is
increasingly used. In a meta-analysis, it was previously found
that proton therapy results in similar survival rates as stereo-
tactic body radiation therapy.9 In another publication, the
influence of different breathing suppression methods was
investigated in a PSPT, IMPT, and stereotactic radiotherapy
treatment planning study.34 Both proton techniques were
superior in sparing the normal tissue when compared with
SBRT. However, the differences were small, and improved
local control rates needed clinical validation. More recent
publications report that PSPT and especially IMPT do benefit
from the superior dose distribution and result in a significant
normal tissue sparing.54,55
Within our current dataset, there were individual cases
(stage IIA and IIIA) that reached MTD levels well above 100
Gy with any of the three modalities. Subgroup analysis did
not show a significantly higher proton dose level for tumors
with different staging or tumor size. This again indicates that
the best treatment modality could be difficult to predict
beforehand and should be investigated on an individual basis.
Future research should preferably include other modalities
such as IMPT or even C-ion radiotherapy. The ROCOCO
consortium is considering to do so with the datasets and
methods presented here. However, up to this date, we have
not found a reliable method to calculate treatment plans for
these new treatment modalities when delivered to moving
lung tumors.
The evidence for the dosimetric improvements of PT is
still hampered by sufficient clinically validated results.13–19,56
However, it is possible to use highly accurate dose calcula-
tions and well-established predictive radiobiological mod-
els57–59 in an in silico approach as a surrogate to determine
the (cost-)effectiveness of PT with sufficient reliability. A
signal in that direction is the fact that the in silico approach
used in this study was acknowledged and justified by the
Dutch Health Care Insurance Board (CVZ)60 as a vital sup-
plement to prospective RCTs.
Recently published studies show the potential cost-
effectiveness of PT in NSCLC. However, they emphasize the
uncertainty in determining this and the probability of making
a wrong decision with regard to establishing a particle cen-
ter.61 It is, therefore, important that when new evidence
becomes available, reassessment of the (cost-)effectiveness
of PT in lung cancer should be carried out. Next, the theo-
retical benefit should be confirmed by clinical evidence from
well-designed prospective studies. We argue that the results
of in silico trials such as the one currently presented aid to
choose the most relevant areas of research for RCTs involv-
ing proton therapy.
CONCLUSIONS
By using an in silico approach, we found that while
maintaining a good coverage of the target, proton radiother-
apy significantly reduced the dose to the normal tissue, as
indicated by a lower ID, when compared with conventional or
intensity-modulated photon therapy for NSCLC patients.
Furthermore, the presented data show that dose escala-
tion is possible and that an increased local tumor control can
be expected, hence improving survival. We believe that
carefully designed RCTs should now be performed to vali-
date these results.
The current findings provide an incentive to investigate
other tumor sites and modalities such as C-ion radiotherapy in
an in silico set-up. For NSCLC patients, the possibilities of
hypofractionated delivery schedules could be investigated as
well. Finally, because investment costs are high, it would be




The clinical target volume (CTV) was defined as the
GTV with a margin of 5 mm. Next, the individual, anisotro-
pic planning target volume (PTV) margins for photons (Eq.
A1) were calculated in three directions (CC, LR, and AP)
using a margin recipe.62
MPTV  2.5    0.72  A2/8 (A1)
with  the overall standard deviation (SD) of the systematic
errors,  the overall SD of the random errors and A the
peak-to-peak amplitude of the tumor. We used the systematic
and random set-up errors as determined in MAASTRO’s
clinical setting. Because the midventilation CT was used,
there was no systematic motion error included.
Proton Treatment Planning
The passive-scattered proton plans were planned using
the XiO TPS (v4.2.1, CMS Software). In passive-scattered
proton radiotherapy, each beam delivers a homogenous dose
to the target volume. To spread-out the dose to normal tissues
each plan consists of at least two, but preferably three, beam
directions. Although range uncertainties and setup errors are
taken into account in the treatment planning process, the use
of multiple beam directions minimizes the risk of underdos-
ing the target due to unexpected density variations, for ex-
ample, heavy breathing or a substantial change in the average
tumor position with respect to the patient anatomy as used for
treatment planning.
Given a midventilation CT scan of the tumor and a
description of the breathing-induced excursion from this
position in all three directions, treatment planning of proton
radiotherapy at MGH is a two-step process. As we may
choose to treat only a subset of fields on any given treatment
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 Protons Versus Photons in NSCLC Treatment
Copyright © 2011 by the International Association for the Study of Lung Cancer 173
day, it is important that each field separately ensures target
coverage.
First, for each beam, we conform the 95% isodose level
as closely as possible to the target, that is, the CTV. The
aperture shape for each beam is chosen to conform the 95%
isodose level in all lateral directions. The proton beam range
and range compensator are chosen to conform distally (down-
stream) to the target volume. The radiological “thickness” of
the target (in the depth direction) determines the choice of
modulation width of the spread-out Bragg peak. In our center,
we employ M98 for the definition of modulation, that is, the
distance between the proximal 98% and the distal 90%
isodose level. Because of the nature of passive-scattered
proton radiotherapy, tight proximal coverage cannot be
achieved except for those regions where the radiological
thickness equals the maximum thickness.
Second, margins were applied to the aperture, the range
compensator, and both the range and modulation width.
Range uncertainties of 3.5% and 1 mm were applied.63 The
same range uncertainty to the modulation width was applied,
taking into account that the increase in range already trans-
lated into an increase in necessary modulation width. For
example, a field with a range of 16 cm and modulation of 10
cm after step one will have a range and modulation width of
16.8 and 11.2 cm, respectively.
Aperture expansion and range compensator smearing
was applied,64 meaning that the safety margin is typically less
than the summation of setup error and half the peak-to-peak
breathing amplitude. Aperture expansion (i.e., lateral margin-
ing) compensates for setup errors of the tumor in the lateral
direction with respect to the central beam axis. Range com-
pensator smearing (i.e., distal margining) is applied to take
into account the effect of the shift in the patient density
distribution and the detrimental effects of these density varia-
tions on distal target coverage. The overshoot due to smearing
depends on the local variation in the range compensator thick-
ness and hence is not uniform across the lateral extent of a field.
The exact magnitude of lateral and distal margining depends on
the extent of the breathing motion but will never be less than the
expected maximum setup error, refer to Table A1.
Our TPS only allows a single uniform value for smear-
ing on a per range compensator basis. Lateral aperture mar-
gins differed depending on the breathing motion in a specific
direction. All patients’ plans consisted of fields in the trans-
versal plane only.
Conformity Index
Assessment of the differences in conformity when
comparing treatment plans from different modalities has
been published before.30 To compare target coverage and
unwanted dose to the noncritical as well as the critical
normal tissue (OARs), we chose to use the “conformation
number” (CN).31
The CN takes into account the quality of tumor irradi-
ation as indicated by the first part of the equation (Eq. A2)









where VT,ref is the volume of the target receiving a dose equal
to or greater than the reference dose, VT is the volume of the
target, and Vref is the overall volume receiving a dose equal to
or greater than the reference dose or target dose.29 The
reference dose was chosen to be 95% of the PD to the PTV
and the CTV was again chosen as the target volume. For
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